A detailed history of Price T Rowe Associates Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,203,968 shares of ITCI stock, worth $82.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,203,968
Previous 1,260,897 4.51%
Holding current value
$82.5 Million
Previous $90.3 Million 7.74%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$64.37 - $75.65 $3.66 Million - $4.31 Million
-56,929 Reduced 4.51%
1,203,968 $83.3 Million
Q4 2023

Feb 14, 2024

BUY
$46.37 - $73.65 $28 Million - $44.5 Million
604,328 Added 92.04%
1,260,897 $90.3 Million
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $10,990 - $13,525
211 Added 0.03%
656,569 $34.2 Million
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $6.15 Million - $7.47 Million
112,424 Added 20.67%
656,358 $41.6 Million
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $516,708 - $672,311
11,797 Added 2.22%
543,934 $29.5 Million
Q4 2022

Feb 14, 2023

BUY
$44.07 - $54.45 $7.98 Million - $9.87 Million
181,181 Added 51.62%
532,137 $28.2 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $13.2 Million - $18.6 Million
310,214 Added 761.41%
350,956 $16.3 Million
Q2 2022

Aug 15, 2022

BUY
$43.0 - $65.64 $44,720 - $68,265
1,040 Added 2.62%
40,742 $2.33 Million
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $136,093 - $218,122
3,513 Added 9.71%
39,702 $2.43 Million
Q4 2021

Feb 14, 2022

SELL
$35.2 - $53.42 $152,521 - $231,468
-4,333 Reduced 10.69%
36,189 $1.89 Million
Q3 2021

Nov 15, 2021

BUY
$28.72 - $42.49 $122,892 - $181,814
4,279 Added 11.81%
40,522 $1.51 Million
Q2 2021

Aug 16, 2021

SELL
$29.3 - $44.5 $118,547 - $180,047
-4,046 Reduced 10.04%
36,243 $1.48 Million
Q1 2021

May 17, 2021

BUY
$30.8 - $39.51 $271,009 - $347,648
8,799 Added 27.94%
40,289 $1.37 Million
Q4 2020

Feb 16, 2021

BUY
$23.34 - $32.22 $734,976 - $1.01 Million
31,490 New
31,490 $1 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $6.47B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.